Discussion
An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now recruiting participants at sites in five countries. The Phase 2 trial, dubbed RENEW (NCT06968845), aims to enroll approximately 120 people with IPF, ages 40 and older. Eligible participants will…